

Zhao Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7378027/publications.pdf>

Version: 2024-02-01

78
papers

2,101
citations

393982

19
h-index

264894

42
g-index

94
all docs

94
docs citations

94
times ranked

2720
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. <i>Blood</i> , 2019, 133, 2465-2477.	0.6	587
2	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. <i>Nature Genetics</i> , 2015, 47, 1061-1066.	9.4	315
3	Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2015, 126, 2186-2192.	0.6	137
4	Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1508-1517.	2.0	112
5	Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. <i>Haematologica</i> , 2020, 105, e210-e212.	1.7	91
6	Genetic Features of Late Onset Primary Hemophagocytic Lymphohistiocytosis in Adolescence or Adulthood. <i>PLoS ONE</i> , 2014, 9, e107386.	1.1	65
7	Relmacabtagene autoleucel (relma ^{ac} cel) CD19 CAR ^{ac} T therapy for adults with heavily pretreated relapsed/refractory large B ^{ac} cell lymphoma in China. <i>Cancer Medicine</i> , 2021, 10, 999-1011.	1.3	50
8	PEG-asparaginase and DEP regimen combination therapy for refractory Epstein ^{ac} Barr virus-associated hemophagocytic lymphohistiocytosis. <i>Journal of Hematology and Oncology</i> , 2016, 9, 84.	6.9	41
9	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12.	6.9	40
10	Central nervous system involvement in adults with haemophagocytic lymphohistiocytosis: a single-center study. <i>Annals of Hematology</i> , 2017, 96, 1279-1285.	0.8	37
11	Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents ^{ac} a life-threatening disease: analysis of 133 cases from a single center. <i>Hematology</i> , 2018, 23, 810-816.	0.7	34
12	Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis. <i>International Journal of Hematology</i> , 2016, 104, 628-635.	0.7	31
13	Early diagnostic value of low percentage of glycosylated ferritin in secondary hemophagocytic lymphohistiocytosis. <i>International Journal of Hematology</i> , 2009, 90, 501-505.	0.7	29
14	Central Nervous System Involvement in Hemophagocytic Lymphohistiocytosis in Adults. <i>Chinese Medical Journal</i> , 2018, 131, 776-783.	0.9	29
15	Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis. <i>Hematology</i> , 2018, 23, 228-234.	0.7	27
16	Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1141-1149.	1.1	25
17	Ruxolitinib ^{ac} combined doxorubicin ^{ac} etoposide ^{ac} methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single ^{ac} arm, multicentre, phase 2 trial. <i>British Journal of Haematology</i> , 2021, 193, 761-768.	1.2	24
18	Primary hemophagocytic lymphohistiocytosis in adults: the utility of family surveys in a single-center study from China. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 17.	1.2	22

#	ARTICLE	IF	CITATIONS
19	Requirement for etoposide in the initial treatment of Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2019, 186, 717-723.	1.2	22
20	Application of an improved flow cytometry-based NK cell activity assay in adult hemophagocytic lymphohistiocytosis. <i>International Journal of Hematology</i> , 2017, 105, 828-834.	0.7	21
21	Requirement for etoposide in the treatment of pregnancy related hemophagocytic lymphohistiocytosis: a multicenter retrospective study. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 50.	1.2	20
22	Epidemiological investigation of hemophagocytic lymphohistiocytosis in China. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 342.	1.2	19
23	Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. <i>American Journal of Hematology</i> , 2022, 97, 458-469.	2.0	19
24	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 38.	6.9	18
25	SOLUBLE ST2 AND CD163 AS POTENTIAL BIOMARKERS TO DIFFERENTIATE PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS FROM MACROPHAGE ACTIVATION SYNDROME. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019008.	0.5	15
26	Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT. <i>Annals of Hematology</i> , 2020, 99, 343-349.	0.8	15
27	The analysis of corneal asphericity (Q value) and its related factors of 1,683 Chinese eyes older than 30 years. <i>PLoS ONE</i> , 2017, 12, e0176913.	1.1	15
28	Genotype characteristics and immunological indicator evaluation of 311 hemophagocytic lymphohistiocytosis cases in China. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 112.	1.2	14
29	Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. <i>Leukemia and Lymphoma</i> , 2018, 59, 77-84.	0.6	13
30	The inhibitory receptors on NK cells and CTLs are upregulated in adult and adolescent patients with secondary hemophagocytic lymphohistiocytosis. <i>Clinical Immunology</i> , 2019, 202, 18-28.	1.4	13
31	Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection. <i>International Immunopharmacology</i> , 2021, 96, 107606.	1.7	11
32	The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis. <i>Leukemia and Lymphoma</i> , 2021, 62, 854-860.	0.6	10
33	Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis. <i>Cancer Biology and Therapy</i> , 2021, 22, 598-606.	1.5	10
34	Clinical Features and Prognostic Risk Prediction of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndrome. <i>Frontiers in Oncology</i> , 2021, 11, 788056.	1.3	10
35	The Revised High-Dose Regimen of Beacop in the Primary Treatment of the Advanced Hodgkin's Lymphoma: A Interim Report. <i>Blood</i> , 2012, 120, 4783-4783.	0.6	9
36	Early Use of Blood Purification in Severe Epstein-Barr Virus-Associated Hemophagocytic Syndrome. <i>Pediatrics</i> , 2020, 145, e20193197.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Adult onset of primary hemophagocytic syndrome in subjects carrying PRF1 mutations. <i>Annals of Hematology</i> , 2012, 91, 1489-1490.	0.8	7
38	Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus. <i>Annals of Hematology</i> , 2019, 98, 2003-2004.	0.8	7
39	Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 492-499.	0.3	6
40	Hemophagocytic Lymphohistiocytosis during the Postpartum Stage of Pregnancy: A Report of Eight Cases. <i>Acta Haematologica</i> , 2019, 141, 55-60.	0.7	6
41	Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 710400.	1.6	6
42	Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 1857-1857.	0.6	6
43	Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative data. <i>British Journal of Haematology</i> , 2020, 191, 269-281.	1.2	5
44	Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis—a dangerous disease. <i>Annals of Hematology</i> , 2020, 99, 1575-1581.	0.8	5
45	Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis. <i>Chinese Medical Journal</i> , 2019, 132, 294-301.	0.9	4
46	Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3478-3478.	0.6	4
47	Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis. <i>Cell Transplantation</i> , 2021, 30, 0963689721110570.	1.2	4
48	A case of lepromatous leprosy complicated by hemophagocytosis misdiagnosed as hemophagocytic lymphohistiocytosis. <i>International Journal of Infectious Diseases</i> , 2014, 23, 28-30.	1.5	3
49	Elevation of CD16+CD56+NK-cells and down-regulation of serum interleukin-21 (IL-21) and IL-1 β after splenectomy in relapsed hemophagocytic lymphohistiocytosis of unknown cause. <i>Hematology</i> , 2017, 22, 1-7.	0.7	3
50	Characteristics of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein-Barr virus disease: favorable responses to rituximab. <i>Bone Marrow Transplantation</i> , 2021, 56, 1449-1451.	1.3	3
51	Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment. <i>Infectious Diseases Now</i> , 2021, 51, 311-313.	0.7	3
52	Non-EBV infection-associated hemophagocytic lymphohistiocytosis: a distinct subgroup where pathogen-directed therapy is essential and favorable outcomes are expected. <i>Leukemia and Lymphoma</i> , 2021, 62, 1657-1663.	0.6	2
53	Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial. <i>Blood</i> , 2012, 120, 2958-2958.	0.6	2
54	The role of allogeneic hematopoietic stem cell transplantation and Epstein-Barr virus infection on the treatment for child primary hemophagocytic lymphohistiocytosis patients with X-linked lymphoproliferative disease: A rare case report and family survey study. <i>Pediatric Transplantation</i> , 2020, 24, e13635.	0.5	2

#	ARTICLE	IF	CITATIONS
55	A Dose Escalation Phase Ia Study of Anti-CD20 Antibody Drug Conjugate, MRC001 in Relapsed/Refractory Advanced Non-Hodgkin Lymphom. <i>Blood</i> , 2021, 138, 2490-2490.	0.6	2
56	Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase â... Clinical Trial. <i>Blood</i> , 2020, 136, 36-37.	0.6	2
57	Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China. <i>Blood</i> , 2020, 136, 39-40.	0.6	2
58	A Study on Early Death Prognosis Model in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-7.	1.1	2
59	Adult primary hemophagocytic lymphohistiocytosis associated with lymphoma. <i>Annals of Hematology</i> , 2020, 99, 663-665.	0.8	1
60	Epstein-Barr virus infection is an important cause of hemophagocytic lymphohistiocytosis during chemotherapy for lymphoma. <i>Infectious Diseases Now</i> , 2021, 51, 310-311.	0.7	1
61	Analysis of Electrocardiogram Among 108 Patients with Brucella. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5251-5254.	0.8	1
62	Chronic active Epstein-Barr virus infection treated with PEG-asparaginase: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 7845-7849.	0.3	1
63	Successful Outcome of a Case of Acute Myeloid Leukemia With t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis. <i>Turkish Journal of Haematology</i> , 2019, 36, 294-296.	0.2	1
64	Neurological symptoms of familial hemophagocytic lymphohistiocytosis type 2. <i>Journal of Integrative Neuroscience</i> , 2020, 19, 131.	0.8	1
65	Development of a Nomogram to Predict the Risk of Chronic Active Epstein-Barr Virus Infection Progressing to Hemophagocytic Lymphohistiocytosis. <i>Frontiers in Medicine</i> , 2022, 9, 826080.	1.2	1
66	A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China. <i>Frontiers in Immunology</i> , 2022, 13, 829878.	2.2	1
67	Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults. <i>Hematological Oncology</i> , 2022, 40, 390-399.	0.8	1
68	Two-year follow-up result of RELIANCE study, a multicenter phase 2 trial of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7529-7529.	0.8	1
69	Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Treatment for Relapsed or Refractory Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2015, 31, 426-433.	0.3	0
70	HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center. <i>Stem Cell Research and Therapy</i> , 2020, 11, 265.	2.4	0
71	Study on Treatment of Lymphoma-Associated Hemophagocytic Syndrome with Fludarabine Combined with Methylprednisolone and Globulin. <i>Blood</i> , 2008, 112, 4956-4956.	0.6	0
72	Early Diagnosis and Treatment of the Patients with Acquired Hemophagocytic Lymphohistiocytosis. <i>Blood</i> , 2008, 112, 3552-3552.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study. <i>Blood</i> , 2021, 138, 2480-2480.	0.6	0
74	Dose of Deferasirox Correlates with Effects but Is Different in Low-Risk Myelodysplastic Syndrome and Aplastic Anemia. <i>Blood</i> , 2021, 138, 3075-3075.	0.6	0
75	The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial. <i>Blood</i> , 2021, 138, 1351-1351.	0.6	0
76	Plasma Lipidome Acts As Diagnostic Marker and Predictor for Cyclosporin Response in Patients with Aplastic Anemia. <i>Blood</i> , 2021, 138, 2199-2199.	0.6	0
77	Efficacy and Safety of Eltrombopag with or without Immunosuppressant in Patients with Relapsed/Refractory Acquired Aplastic Anemia: A Real-World Experience. <i>Blood</i> , 2021, 138, 1124-1124.	0.6	0
78	Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients with Lower-Risk Myelodysplastic Syndrome: A Prospective Cohort Study. <i>Blood</i> , 2021, 138, 1525-1525.	0.6	0